ATLANTA, GA, August 29, 2013 -- Vystar® Corporation (OTC Pink: VYST) ("Vystar" or the "Company"), the exclusive creator of Vytex® Natural Rubber Latex (NRL), a multi-patented, all-natural raw material that contains significantly reduced levels of non-rubber particles and proteins found in natural rubber latex, today announced that the European Patent Office issued a Decision to Grant Vystar's patent application under European Patent Number 1 902 089 titled "Decreasing Allergenicity of Natural Latex Rubber Prior to Vulcanization" greatly expanding the territory covered by the Company's intellectual property portfolio. The mention of the grant was published in the European Patent Bulletin 13/35 dated 28 August 2013.
The patent "Decreasing Allergenicity of Natural Latex Rubber Prior to Vulcanization," is significant not only to the Company but also to European manufacturers who use latex in production of end products as well as consumers who utilize their end products. For manufacturers, the value in using Vytex NRL is multi-faceted. Because Vytex NRL results in a more translucent and cleaner latex following the removal of proteins and non-rubbers, value in utilizing Vytex NRL for manufacturers can been seen in decreased production costs which result from utilizing less chemicals, water and processing to remove proteins, less dyes and perfumes to cover up the yellow color and odor of non-Vytex natural rubber latex. Value to consumers of end products made with Vytex NRL are also significant as they are able to enjoy the benefit of virtually no exposure to the antigenic proteins that can cause allergic reaction and irritation stemming from natural rubber latex, as well as enjoying more appealing appearances with less opaqueness, yellowing and more vibrant color when dyes are used.
Vystar has previously received four (4) US patents and four (4) international patents covering various aspects of the Vytex process and its resulting composition through that process of using aluminum hydroxide with natural rubber liquid latex to remove proteins and unwanted non-rubber materials. On December 4, 2012, USPTO gave Vystar an additional patent on the composition of liquid natural rubber latex with an ultra low level of antigenic proteins (3.0 micrograms per gram).
William Doyle, President and CEO of Vystar® Corporation, commented, "The acceptance of the original composition claims by the European patent office not only protects our IP and substantially augments our patent collection in the selected countries in Europe, where there is a large and expanding manufacturing base, but also solidifies our technology as superior to others in treating liquid natural rubber latex specifically."
He continued, "The global liquid natural rubber latex market is a multi-billion dollar market, and Vytex operates in a niche, premium sector of this market. With this new territory covered by our patents, we are able to show our superiority and true uniqueness, and look forward to showcasing our abilities amongst the competition in areas such as gloves, adhesives, condoms, balloons, garments, cosmetics and may other items across a broad range of industries. Vytex NRL is already used in a variety of products in the EU."
About Vystar Corporation
Based in Duluth, GA, Vystar® Corporation (OTC Pink: VYST) is the exclusive creator of Vytex Natural Rubber Latex (Vytex NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, balloons, surgical and exam gloves, other medical devices and natural rubber latex foam mattresses and pillows. Vystar's SleepHealth and Kiron Sleep Lab LLC acquisitions provide an entry into the health and wellness market. For more information, visit www.vytex.com. www.sleephealthier.com. www.kironsleep.com.
Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.
President and CEO
770-965-0383 x 22
SOURCE: Vystar Corporation